Table 4. Univariate analyses for target failure-free survival, in-lobe failure-free survival, regional failure-free survival, distant metastasis failure-free survival, overall progression-free survival, and overall survival.
stereotactic body radiation therapy (SBRT), genitourinary (GU), gynecologic (GYN), biologically effective dose with alpha-beta ratio of 10 (BED10), target failure-free survival (TFFS), in-lobe failure-free survival (LFFS), regional failure-free survival (RFFS), distant metastasis failure-free survival (DMFS), progression free survival (PFS)
| Univariate Analysis | Overall survival | TFFS | ||
| Factors | HR (95% CI) | P Value | HR (95% CI) | P Value |
| Race | ||||
| Caucasian | Reference | Reference | ||
| African American | * | 0.98 | 0.04 (0.00-437) | 0.51 |
| Age | ||||
| At SBRT | 1.02 (0.99-1.04) | 0.18 | 1.01 (0.97-1.06) | 0.51 |
| At diagnosis | 1.02 (1.00-1.05) | 0.04 | 1.00 (0.97-1.05) | 0.84 |
| Prior treatments | ||||
| None | Reference | Reference | ||
| Had Prior | 0.57 (0.25-1.27) | 0.17 | 1.18 (0.15-9.15) | 0.87 |
| Synch/Metachronous | ||||
| Synchronous | Reference | Reference | ||
| Metachronous | 1.08 (0.48-2.40) | 0.86 | 1.56 (0.20-12.0) | 0.67 |
| Tumor Size | 1.52 (1.21-1.92) | <0.001 | 1.97 (1.49-2.61) | <0.001 |
| Primary Origin | ||||
| Breast | Reference | Reference | ||
| Esophagus | 3.39 (0.83-13.8) | 0.09 | 0.46 (0.05-4.51) | 0.51 |
| GYN | 0.88 (0.22-3.57) | 0.85 | 0.25 (0.03-2.44) | 0.24 |
| Head/Neck | 1.27 (0.39-4.15) | 0.69 | * | 0.97 |
| Sarcoma | 2.20 (0.61-7.91) | 0.23 | 0.46 (0.08-2.78) | 0.40 |
| GU | 0.59 (0.15-2.37) | 0.46 | 0.31 (0.02-1.98) | 0.17 |
| Colorectal | 0.82 (0.27-2.45) | 0.72 | 0.27 (0.07-1.18) | 0.08 |
| Melanoma | 0.92 (0.20-4.16) | 0.91 | * | 0.99 |
| Other | 0.50 (0.09-2.75) | 0.43 | * | 0.98 |
| Histology | ||||
| Adenocarcinoma | Reference | Reference | ||
| Squamous Cell Carcinoma | 1.22 (0.53-2.84) | 0.64 | * | 0.98 |
| Sarcoma | 1.29 (0.60-2.78) | 0.51 | 1.64 (0.49-5.45) | 0.42 |
| Other | 0.73 (0.35-1.54) | 0.41 | 0.34 (0.04-2.75) | 0.31 |
| Number lesions at SBRT | 1.14 (0.84-1.55) | 0.41 | 0.14 (0.02-0.96) | 0.045 |
| BED10 | 0.99 (0.985-0.997) | 0.002 | 0.97 (0.96-0.99) | <0.001 |
| Time to 1st SBRT | 0.995 (0.99-1.00) | 0.07 | 1.00 (0.99-1.01) | 0.65 |
| Post SBRT Chemotherapy | 1.33 (0.76-2.31) | 0.32 | 0.91 (0.30-2.80) | 0.87 |
| Univariate Analysis | LFFS | RFFS | ||
| Factors | HR (95% CI) | P Value | HR (95% CI) | P Value |
| Race | ||||
| Caucasian | Reference | Reference | ||
| African American | 0.30 (0.04-2.16) | 0.23 | 0.66 (0.16-2.27) | 0.56 |
| Age | ||||
| At SBRT | 0.99 (0.97-1.02) | 0.56 | 1.02 (0.99-1.04) | 0.18 |
| At diagnosis | 1.00 (0.97-1.02) | 0.71 | 1.02 (1.00-1.05) | 0.049 |
| Prior treatments | ||||
| None | Reference | Reference | ||
| Had Prior | 2.00 (0.48-8.29) | 0.34 | 0.97 (0.34-2.70) | 0.95 |
| Synch/Metachronous | ||||
| Synchronous | Reference | Reference | ||
| Metachronous | 0.78 (0.45-2.90) | 0.78 | 0.97 (0.38-2.45) | 0.94 |
| Tumor Size | 1.47 (1.21-1.79) | <0.001 | 1.33 (1.09-1.61) | 0.004 |
| Primary Origin | ||||
| Breast | Reference | Reference | ||
| Esophagus | 2.45 (0.54-11.0) | 0.24 | 1.21 (0.27-5.43) | 0.80 |
| GYN | 0.25 (0.03-2.41) | 0.23 | 0.65 (0.15-2.92) | 0.58 |
| Head/Neck | 0.80 (0.20-3.22) | 0.76 | 0.75 (0.23-2.50) | 0.64 |
| Sarcoma | 0.95 (0.21-4.26) | 0.95 | 0.93 (0.25-3.50) | 0.92 |
| GU | 0.63 (0.13-3.12) | 0.57 | 0.31 (0.06-1.69) | 0.17 |
| Colorectal | 1.11 (0.33-3.77) | 0.87 | 0.52 (0.17-1.62) | 0.26 |
| Melanoma | 0.50 (0.05-4.79) | 0.55 | 0.76 (0.14-4.14) | 0.75 |
| Other | 0.23 (0.02-2.21) | 0.20 | 1.04 (0.28-3.88) | 0.95 |
| Histology | ||||
| Adenocarcinoma | Reference | Reference | ||
| Squamous Cell Carcinoma | 0.72 (0.28-1.90) | 0.52 | 0.96 (0.42-2.20) | 0.92 |
| Sarcoma | 0.70 (0.29-1.70) | 0.43 | 0.69 (0.29-1.68) | 0.42 |
| Other | 0.41 (0.14-1.18) | 0.097 | 0.38 (0.13-1.08) | 0.07 |
| Number lesions at SBRT | 0.86 (0.64-1.15) | 0.30 | 0.50 (0.32-0.77) | 0.002 |
| BED10 | 0.994 (0.99-1.002) | 0.12 | 0.99 (0.98-1.00) | 0.005 |
| Time to 1st SBRT | 0.998 (0.99-1.00) | 0.55 | 0.99 (0.986-1.00) | 0.049 |
| Post SBRT Chemotherapy | 2.25 (1.21-4.19) | 0.01 | 1.99 (1.04-3.43) | 0.04 |
| Univariate Analysis | DMFS | PFS | ||
| Factors | HR (95% CI) | P Value | HR (95% CI) | P Value |
| Race | ||||
| Caucasian | Reference | Reference | ||
| African American | 0.88 (0.27-2.84) | 0.83 | 0.58 (0.21-1.58) | 0.29 |
| Age | ||||
| At SBRT | 1.01 (0.99-1.03) | 0.47 | 1.00 (0.98-1.02) | 0.94 |
| At diagnosis | 1.01 (0.99-1.02) | 0.39 | 1.00 (0.99-1.02) | 0.62 |
| Prior treatments | ||||
| None | Reference | Reference | ||
| Had Prior | 1.39 (0.43-4.49) | 0.59 | 1.08 (0.62-2.24) | 0.83 |
| Synch/Metachronous | ||||
| Synchronous | Reference | Reference | ||
| Metachronous | 0.59 (0.28-1.27) | 0.18 | 0.69 (0.38-1.24) | 0.21 |
| Tumor Size | 1.17 (0.93-1.47) | 0.18 | 1.31 (1.14-1.52) | <0.001 |
| Primary Origin | ||||
| Breast | Reference | |||
| Esophagus | 1.33 (0.35-5.03) | 0.67 | 0.76 (0.27-2.15) | 0.61 |
| GYN | 0.78 (0.21-2.92) | 0.71 | 0.55 (0.21-1.42) | 0.22 |
| Head/Neck | 0.29 (0.08-1.07) | 0.06 | 0.36 (0.15-0.85) | 0.02 |
| Sarcoma | 1.47 (0.47-4.59) | 0.51 | 0.64 (0.26-1.53) | 0.31 |
| GU | 0.44 (0.12-1.65) | 0.22 | 0.21 (0.07-0.64) | 0.01 |
| Colorectal | 0.39 (0.14-1.11) | 0.08 | 0.39 (0.18-0.82) | 0.01 |
| Melanoma | 1.30 (0.31-5.46) | 0.72 | 0.79 (0.26-2.36) | 0.67 |
| Other | 0.62 (0.17-2.30) | 0.47 | 0.38 (0.13-1.06) | 0.06 |
| Histology | ||||
| Adenocarcinoma | Reference | Reference | ||
| Squamous Cell Carcinoma | 1.00 (0.56-1.82) | 0.99 | 0.73 (0.38-1.40) | 0.35 |
| Sarcoma | 1.37 (0.87-2.15) | 0.17 | 0.94 (0.54-1.62) | 0.81 |
| Other | 1.16 (0.65-2.06) | 0.62 | 0.65 (0.35-1.20) | 0.17 |
| Number lesions at SBRT | 0.56 (0.38-0.82) | 0.003 | 0.60 (0.47-0.77) | <0.001 |
| BED10 | 1.00 (0.99-1.01) | 0.80 | 0.996 (0.99-1.00) | 0.08 |
| Time to 1st SBRT | 0.998 (0.99-1.00) | 0.48 | 0.998 (0.994-1.00) | 0.20 |
| Post SBRT Chemotherapy | 2.59 (1.46-4.61) | 0.001 | 2.19 (1.44-3.31) | <0.001 |